Meet the Coastland Dental team, where advanced technology meets compassionate care in the heart of Burbank. “We are always ...

One such product gaining attention in 2025 is Herpesyl, a nutritional supplement that claims to not just suppress herpes ...

H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will be holding one-on-one meetings with investors.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities ...

Nadav is a fantastic addition to the Board,” said Company CEO and Chairman of the Board Mr. Uzi Sofer. “He has spent many years in a position much like ours, at the helm of a public company innovating ...

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven ...

In March 2025, the investigator sponsored Phase 0/1 trial was expanded into newly diagnosed GBM patients with epidermal growth factor receptor (EGFR) alterations. The trial is sponsored by the Ivy ...

REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, ...